Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy - Wikidata - wikimedia - TriplyDB

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

http://www.wikidata.org/entity/Q37653146

about

Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney Identification of glucose-derived cross-linking sites in ribonuclease A Pathophysiology of diabetic retinopathy Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats Leukocyte-mediated endothelial cell injury and death in the diabetic retina The role of glycation in the pathogenesis of diabetic polyneuropathy Advanced glycation: an important pathological event in diabetic and age related ocular disease Presence and Risk Factors for Glaucoma in Patients with Diabetes.Early glycation products produce pentosidine cross-links on native proteins. novel mechanism of pentosidine formation and propagation of glycation.Diabetic macular edema: classification, medical and laser therapy.Current and future pharmacological intervention for diabetic retinopathy.Molecular mechanisms of diabetic vascular complications Protective effect of quercetin on the morphology of pancreatic beta-cells of streptozotocin-treated diabetic rats Dyslipidemia and diabetic retinopathy.Rodent Hyperglycemia-Induced Inner Retinal Deficits are Mirrored in Human Diabetes Therapeutic interventions and oxidative stress in diabetes Mass spectrometric quantification of amino acid oxidation products identifies oxidative mechanisms of diabetic end-organ damage.Expression patterning reveals retinal inflammation as a minor factor in experimental retinopathy of ZDF rats.Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop.Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy Histamine, ZO-1 and increased blood-retinal barrier permeability in diabetic retinopathy The maillard reaction in eye diseases.Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF.Diabetic retinopathy - An update.Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE).Medical treatment of diabetic retinopathy.Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus Litsea japonica extract inhibits neuronal apoptosis and the accumulation of advanced glycation end products in the diabetic mouse retina.Antioxidative and aldose reductase-inhibitory effects of a fermentation filtrate of Rubus coreanus Aminoguanidine reverses the loss of functional hyperemia in a rat model of diabetic retinopathy.Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.Topiramate Protects Pericytes from Glucotoxicity: Role for Mitochondrial CA VA in Cerebromicrovascular Disease in Diabetes.Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus.Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.Zingiber officinale attenuates retinal microvascular changes in diabetic rats via anti-inflammatory and antiangiogenic mechanisms.Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis Retinylamine Benefits Early Diabetic Retinopathy in Mice

P2860

Q24292412-97291132-7590-40A7-9BD7-BFAA407B133B Q24647582-9A9D1054-6D88-4022-AD34-712FA8ECBDFE Q26865897-0157BD8E-E6FE-46F3-9509-DBAB0AAF1A4F Q28213026-B5692E95-6A54-4C7A-8F7F-3A69FFF40DB0 Q28345653-1EDE0462-DADE-4754-A5CD-B3AC9C1D2EA1 Q28365458-6194990E-18D0-490A-A44E-9799E22D2CC7 Q28365776-829CBC66-EA63-4025-852D-CD760F03B328 Q30244246-3922D216-1D31-4ACB-96E6-60662EBB0009 Q31561110-721AC55C-CD0E-47CC-9AFA-8FA033DC3E79 Q33208471-14A8AA30-3BB6-48EB-B946-4F39378CF028 Q33216425-9CB293A2-0735-4BA6-919A-D6F9A3F02904 Q33558421-96CE8360-83D7-4470-9AC8-EDB17EEE8625 Q33630001-F5BD854B-11CE-4367-A514-93069A0D126E Q33776171-6FE42308-9F46-4B54-B5AA-A8BE42ED0FFA Q33782405-956238D6-E331-408C-BE2C-82C66686D582 Q33870395-7B039D68-D66C-4F03-B514-927AD341A57A Q33922502-B85113D7-D77C-4769-B796-BF2FD6C89264 Q34023099-09A2B6EB-E163-4D96-A40C-31DFA65D8126 Q34081378-3ADF55F2-C617-4A8C-9875-73C4EEE64FEF Q34090428-E8B71EC4-3F0A-47B4-A5EB-9D14A232B4FB Q34211271-B36FAB83-E4CB-4F3B-8E54-B92CA3A54AB9 Q34436018-BC78423C-3620-4EEA-9CEE-6620193AFA65 Q34481838-4B71A480-F29B-4E65-9ABA-DA8A6C859A50 Q34733351-5F943BEC-1FCA-45E3-8A51-0E31730AF243 Q34957902-58BE7E15-81A8-4BA1-A6F7-CF5FA8AFD44B Q35133201-5A668E77-287B-496F-B852-380CC4CE7F6F Q35175679-EDAD686E-1C8F-46EF-A542-9AAC365986BA Q35530622-AEA21221-5416-4D7E-981E-26413E67FB01 Q35610369-A35CF09E-4010-4ABD-A58D-4554DDC7F430 Q35628566-216972EE-D9E3-4890-BCE9-33D1E84213BC Q35653459-BD1F289B-B9E2-45A8-AF63-3AB1EAD6A297 Q35661653-6BEE0FAD-E178-4FD8-9FF4-BD081EC45711 Q35764706-18F04FE9-D698-4496-9950-1721A304C23A Q35831554-3C6CBD83-0DED-4529-86AB-AF8AC2620478 Q35833696-1D45285B-6483-4009-82A3-06B2F3A053E5 Q36001244-470200C7-F2C9-4EDF-854E-85DF3EC4C9AB Q36023488-3E76F23F-9A8F-4947-84F1-544692E7F1D4 Q36049918-B9A5D8BA-53C1-40A2-853A-1077DF13ACD2 Q36052417-19E27936-EB27-400C-8D2F-1C8DCFF92821 Q36065113-60AB336C-1DB6-4490-91EA-CFD2DAC2AD0B

P2860

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

http://www.wikidata.org/entity/Q37653146

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 1991

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

@en

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.

@nl

type

label

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

@en

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.

@nl

prefLabel

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

@en

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.

@nl

P1433

Q37653146-51472BB1-1990-41AD-B557-62DFB98286EB

P1476

Q37653146-8BD54BCD-9727-44C1-9410-F193548EF4EB

P2093

Q37653146-12BC1E0D-577A-41B3-9EFE-80150A8DF019

Q37653146-1E88B192-B6D8-4A29-B5FC-3070A1B4753E

Q37653146-6A544369-745D-40B2-8B80-1D1F180072CD

Q37653146-6AABFCBB-D4D6-47BA-A817-0C12C758F86B

Q37653146-B89E147B-7C1C-41A3-97A3-C64994190D1B

P2860

Q37653146-5096ED4E-FE11-4558-8002-C0947A09615D

Q37653146-5F84E151-5332-42CA-9DF1-8FA986995325

Q37653146-937964F8-41E8-4DCC-AFE0-F3B9AF0EB105

Q37653146-A3D08246-EFE3-4A92-9F6F-01BE78B7374A

Q37653146-A49A5C7F-1B34-4E5D-97FF-DD36008AF74F

Q37653146-AEE26E2F-AEEC-4D8A-935E-10F58DB8F657

Q37653146-C080586C-5500-4F60-A052-81AB0E048CA7

Q37653146-C296E985-F1D9-4690-8E71-2D83CEEE0213

Q37653146-CB696549-FD22-40C9-932A-196F2219B47E

Q37653146-E056B971-0B0B-47CD-A73A-B89FCFDCFD7B

P304

Q37653146-484107B6-1BD1-4B83-8E3C-303FDA0B2603

P31

Q37653146-F7DE14B7-5EE8-4921-80D0-FB530D33A756

P356

Q37653146-26A6CC13-AF64-4682-8A93-4916174FD1A1

P407

Q37653146-73348CAF-D63D-4BD2-AAD5-99EF030EA5C2

P433

Q37653146-724FF222-D4EC-410F-851A-5DCBD5B0551E

P478

Q37653146-2217B52F-737A-4F69-B713-A6576683BE0E

P577

Q37653146-8E25BF90-1C69-479C-8F02-079511D6E988

P5875

Q37653146-7D30A22B-B2BB-4EB1-92C8-80B96AB5D196

P698

Q37653146-F8F5BB28-CDBB-4CA0-9F24-753C9466C1C4

P932

Q37653146-2DAFB599-C01F-475B-968C-054D22B9DE58

P356

PNAS.88.24.11555

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

@en

P2093

H P Hammes

http://www.w3.org/2001/XMLSchema#string

K Federlin

http://www.w3.org/2001/XMLSchema#string

K Geisen

http://www.w3.org/2001/XMLSchema#string

M Brownlee

http://www.w3.org/2001/XMLSchema#string

S Martin

http://www.w3.org/2001/XMLSchema#string

P2860

Accelerated age-related browning of human collagen in diabetes mellitus

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications

Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties.

Glycosylation products as toxic mediators of diabetic complications.

Pathogenesis of diabetic retinopathy.

Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications.

The pharmacology of aldose reductase inhibitors.

Clinicopathologic correlations in diabetic retinopathy. II. Clinical and histologic appearances of retinal capillary microaneurysms.

P304

11555-11558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.88.24.11555

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P577

1991-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21392860

http://www.w3.org/2001/XMLSchema#string

P698

1763069

http://www.w3.org/2001/XMLSchema#string

P932

53174

http://www.w3.org/2001/XMLSchema#string